Dose escalation of lenalidomide in relapsed or refractory acute leukemias

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4919-4925

  Blum, William ^a   Klisovic, Rebecca B ^a   Becker, Heiko ^a   Yang, Xiaoxia ^a   Rozewski, Darlene M ^a   Phelps, Mitch A ^a   Garzon, Ramiro ^a   Walker, Alison ^a   Chandler, Jason C ^a   Whitman, Susan P ^a   Curfman, John ^a   Liu, Shujun ^a   Schaaf, Larry ^a   Mickle, Jon ^a   Kefauver, Cheryl ^a   Devine, Steven M ^a   Grever, Michael R ^a   Marcucci, Guido ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HUMAN; HYPOTENSION; INFECTIOUS COMPLICATION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; THALIDOMIDE;

EID: 79951908984     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.3339     Document Type: Article

References (38)

1. Breems DA, Van Putten WL, Huijgens PC, et al: Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969-1978, 2005
2. Michallet M, Thomas X, Vernant JP, et al: Longterm outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: A retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 26:1157-1163, 2000
3. Kebriaei P, Kline J, Stock W, et al: Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 35:965-970, 2005 (Pubitemid 40711832)
4. Sierra J, Storer B, Hansen JA, et al: Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 89:4226-4235, 1997 (Pubitemid 27220974)
5. Blum W, Bolwell BJ, Phillips G, et al: High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. Biol Blood Marrow Transplant 12:61-67, 2006 (Pubitemid 43034098)
6. Crane E, List A: Lenalidomide: An immunomodulatory drug. Future Oncol 1:575-583, 2005
7. Bartlett JB, Tozer A, Stirling D, et al: Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93:613-619, 2005 (Pubitemid 41486449)
8. Lapalombella R, Andritsos L, Liu Q, et al: Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115:2619-2629, 2010
9. Wei S, Chen X, Rocha K, et al: A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 106:12974-12979, 2009
10. Wu L, Adams M, Carter T, et al: Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximabtreated CD20+ tumor cells. Clin Cancer Res 14:4650-4657, 2008
11. Pellagatti A, Jädersten M, Forsblom AM, et al: Lenalidomide inhibits the malignant clone and upregulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 104:11406-11411, 2007 (Pubitemid 47175153)
12. Knight R: IMiDs: A novel class of immunomodulators. Semin Oncol 32:S24-S30, 2005 (suppl 5)
13. Ramsay AG, Johnson AJ, Lee AM, et al: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 118:2427-2437, 2008 (Pubitemid 351949771)
14. List A, Dewald G, Bennett J, et al: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355:1456-1465, 2006 (Pubitemid 44511560)
15. Adès L, Boehrer S, Prebet T, et al: Efficacy and safety of lenalidomide in intermediate-2 or highrisk myelodysplastic syndromes (MDS) with 5q deletion: Results of a phase 2 study. Blood 113:3947-3952, 2009
16. Raza A, Reeves JA, Feldman EJ, et al: Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111:86-93, 2008
17. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
18. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
19. Wetzler M, Dodge RK, Mrózek K, et al: Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience. Blood 93:3983-3993, 1999 (Pubitemid 29249848)
20. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002 (Pubitemid 34627197)
21. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
22. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087, 2008
23. Fehniger TA, Byrd JC, Marcucci G, et al: Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 113:1002-1005, 2009
24. Chen N, Lau H, Kong L, et al: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475, 2007 (Pubitemid 350115306)
25. Dahut WL, Aragon-Ching JB, Woo S, et al: Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 49: 650-660, 2009
26. Chang DH, Liu N, Klimek V, et al: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 108:618-621, 2006 (Pubitemid 44061362)
27. Estey E, Thall P, David C: Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 40:S9-S12, 1997 (suppl)
28. Litzow MR, Othus M, Cripe LD, et al: Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: A report from the Eastern Cooperative Oncology Group. Br J Haematol 148:217-225, 2010
29. Giles F, Vey N, DeAngelo D, et al: Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood 114: 4027-4033, 2009
30. Burnett AK, Russell NH, Kell J, et al: European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 28:2389-2395, 2010
31. Kantarjian HM, Erba HP, Claxton D, et al: Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28:549-555, 2010
32. Cashen AF, Schiller GJ, O'Donnell MR, et al: Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28:556-561, 2010
33. Blum W, Garzon R, Klisovic RB, et al: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473-7478, 2010
34. Gorgun G, Ramsay AG, Holderried TA, et al: E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 106:6250-6255, 2009
35. Awan FT, Lapalombella R, Trotta R, et al: CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115:1204-1213, 2010
36. Zhu D, Corral LG, Fleming YW, et al: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57:1849-1859, 2008
37. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al: Immunomodulatory drugs stimulate natural killercell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the antitumour activity of rituximab in vivo. Br J Haematol 140:36-45, 2008 (Pubitemid 350233246)
38. Wadia PP, Coram M, Armstrong RJ, et al: Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood 115:2077-2087, 2010